Research Article | Volume: 4, Issue: 3, March, 2014

Synthesis of Methyl 2-Cinnamamido-3-Hydroxy Propanoate Having Activity against P388 Leukemia Cells

Teni Ernawati Yulia Anita Puspa Dewi Lotulung and Muhammad Hanafi   

Open Access   

Published:  Feb 27, 2014

DOI: 10.7324/JAPS.2014.40318
Abstract

Cinnamic acid derivative compound was investigated for the anti-cancer inhibitory activity. To be able to obtain compounds that have bioactivity as above, it is needed to study quantitative structure-activity relationship (QSAR) which is the process by which the chemical structure is quantitatively correlated with biological activity/chemical reactivity. Chemical methods used in synthesizing the chemical of methyl trans-cinnamate derivatives are tailored to match their targeted bioactivities. Here, we investigated the anti-cancer inhibitor compound with the method amidation of cinnamic acid derivative compounds. In this reaction we use two steps to get the target product. Firstly, we hydrolize of methyl trans-cinnamate to cinnamic acid. That reaction has a yield 85.5 % and secondly, we amidate of cinnamic acid to metil 2-cinnamamido-3-hydroxy propanoate has a yield of 51.5%. The compound of metil 2-cinnamamido-3-hydroxy propanoate showed against P388 leukemia cells inhibitory activity with IC50 = 10.78 µg/mL.


Keyword:     methyl trans-cinnamate cinnamic acid synthesis amidation NN diethylcinnamamideanti-cancer P388 leukemia cells.


Citation:

Research Center for Chemistry - Indonesian Institute of Sciences (LIPI) Kawasan Puspiptek Serpong, Tangerang Selatan 15314, Indonesia.

Copyright:The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text

Reference

Article Metrics

377 Absract views 8 PDF Downloads 385 Total views

   Abstract      Pdf Download

Related Search

By author names

Citiaion Alert By Google Scholar

Name Required
Email Required Invalid Email Address

Comment required